Combination Therapy Comprising A CDK4/6 Inhibitor and a P13K Inhibitor for Use in the Treatment of Cancer

ABSTRACT

A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer.

FIELD OF THE DISCLOSURE

A combination of a cyclin dependent kinase 4/6 (CDK4/6) inhibitor and aPhosphatidylinositol 3-Kinase (PI3Kinase) inhibitor for the treatment ofsolid tumors and hematological malignancies. This disclosure alsorelates to the use of the combination thereof, in the management ofhyperproliferative diseases like cancer.

RELATED BACKGROUND ART

Cyclin dependent kinase 4/6 (CDK4/6) inhibitors are described in, forexample, WO2007/140222 and WO2010/020675, which are hereby incorporatedby reference in entirety.

Phosphatidylinositol 3-Kinase (PI3Kinase) inhibitors are described in,for example, WO2004/048365, WO2007/084786, WO2004/096797, WO2010/029082,WO2006/122806 which is hereby incorporated by reference in entirety.

BRIEF SUMMARY OF THE DISCLOSURE

The disclosure provides a combination comprising a first agent thatinhibits the CDK4/6 pathway and a second agent that inhibits PBKinase.In another aspect, the disclosure provides combinations includingpharmaceutical compositions comprising a therapeutically effectiveamount of a first agent that inhibits CDK4/6, a second agent thatinhibits PBKinase, and a pharmaceutically acceptable carrier.

Furthermore, the present disclosure provides for the use of atherapeutically effective amount of a combination comprising a firstagent that inhibits the CDK4/6 pathway and a second agent that inhibitsPBKinase, or a pharmaceutically acceptable salt or pharmaceuticalcomposition thereof, in the manufacture of a medicament for treatingcancer.

The present disclosure has a therapeutic use in the treatment of variousproliferative diseases.

The above combinations and compositions can be administered to a systemcomprising cells or tissues, as well as a human patient or and animalsubject.

In one embodiment, the first agent that inhibits the CDK4/6 pathway isCompound A which is7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylicacid dimethylamide or pharmaceutically acceptable salt(s) thereof.Compound A is described by Formula A:

or pharmaceutically acceptable salt(s) thereof.

In another embodiment, the second agent that inhibits PI3Kinase isCompound B1 described by Formula B1:

or pharmaceutically acceptable salt(s) thereof.

Compound B1 has been described with several names, such as4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine;5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin2-ylamine;5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine;or CAS name5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-pyrimidinamine.

In another embodiment, the second agent that inhibits PI3Kinase isCompound B2 described by Formula B2:

or pharmaceutically acceptable salt(s) thereof.

Compound B2 is known as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the results when the combination of Compound A andCompound B1 or Compound B2, is used to treat MDA-MB-453 cells. Theresulting inhibition values were used by CHALICE software to generateInhibition and ADD Excess Inhibition matrices, as well as theisobolograms.

FIG. 2 illustrates the results when the combination of Compound A andCompound B1 or Compound B2, is used to treat HCT-116 cells. Theresulting inhibition values were used by CHALICE software to generateInhibition and ADD Excess Inhibition matrices, as well as theisobolograms.

FIG. 3 illustrates the results when the combination of Compound A andCompound B1 or Compound B2, is used to treat MCF-7 cells. The resultinginhibition values were used by CHALICE software to generate Inhibitionand ADD Excess Inhibition matrices, as well as the isobolograms.

FIG. 4 illustrates the results when the combination of Compound A andCompound B2, is used to treat T47-D cells. The resulting inhibitionvalues were used by CHALICE software to generate Inhibition and ADDExcess Inhibition matrices, as well as the isobolograms.

DETAILED DESCRIPTION OF THE DISCLOSURE

The disclosure provides a combination comprising a first agent thatinhibits the CDK4/6 pathway and a second agent that inhibits PI3Kinase.In another aspect, the disclosure provides combinations includingpharmaceutical compositions comprising a therapeutically effectiveamount of a first agent that inhibits CDK4/6, a second agent thatinhibits PI3Kinase, and a pharmaceutically acceptable carrier.

Furthermore, the present disclosure provides for the use of atherapeutically effective amount of a combination comprising a firstagent that inhibits the CDK4/6 pathway and a second agent that inhibitsPBKinase, or a pharmaceutically acceptable salt or pharmaceuticalcomposition thereof, in the manufacture of a medicament for treatingcancer.

The present disclosure has a therapeutic use in the treatment of variousproliferative diseases.

The above combinations and compositions can be administered to a systemcomprising cells or tissues, as well as a human patient or and animalsubject.

In one embodiment, the first agent that inhibits the CDK4/6 pathway isCompound A which is7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylicacid dimethylamide or pharmaceutically acceptable salt(s) thereof.Compound A is described by Formula A:

In another embodiment, the second agent that inhibits PI3Kinase isCompound B1 described by Formula B1:

or pharmaceutically acceptable salt(s) thereof.

Compound B1 has been described with several names, such as4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine;5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin2-ylamine;5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine;or CAS name5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-pyrimidinamine.

In another embodiment, the second agent that inhibits PI3 Kinase isCompound B2 described by Formula B2:

or pharmaceutically acceptable salt(s) thereof.

Compound B2 is known as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide).

In another embodiment, the present disclosure includes a method oftreating a hyperproliferative disease, preferably cancer. The compoundsof the present disclosure inhibitors of CDK4/6 and PI3K, and thereforemay be capable of treating diseases wherein the underlying pathology is(at least in part) mediated by activated CDK4/6 and/or PI3K pathway.Such diseases include cancer and other diseases in which there is adisorder of cell proliferation, apoptosis, or differentiation.

Thus the combination of the present disclosure may be useful in thetreatment of RB+ve (retinoblastoma protein positive) tumours, includingtumours harbouring activating mutations in Ras, Raf, Growth FactorReceptors, PI3K,or over-expression of Growth Factor Receptors, orinactivation of p16. The compounds of the present disclosure may also beuseful in the treatment of tumours with amplifications of CDK4 and CDK6genes as well as, tumours over-expressing cyclin partners of the cyclindependent kinases. The compounds of the present disclosure may also beuseful in the treatment of RB−ve tumours.

The combination of the present disclosure may also be useful in thetreatment tumours with genetic aberrations that activate the CDK4/6kinase activity. These include, but are not limited to, cancers withD-cyclin translocations such as mantle cell lymphoma and multiplemyeloma, D-cyclin amplifications such as breast cancer and squamous cellesophageal cancer, CDK4 amplifications such as liposarcoma, CDK6amplifications or overexpressions such as T-cell lymphoma and p16inactivation such as melanoma, non-small cell lung cancer and pancreaticcancer.

The combination of the present disclosure may be useful in the treatmentof cancers that have genetic aberrations in the upstream regulators ofD-cyclins, where the defect results in an increase of D-cyclinsabundance, can also be considered for treatment. These include, but arenot limited to, acute myeloid leukemia with FLT3 activation, breastcancers with Her2/neu overexpression, ER dependency or triple negativephenotype, colon cancers with activating mutations of the MAPK, PI3K orWNT pathway, melanomas with activating mutations of MAPK pathway, nonsmall cell lung cancers with activating aberrations of EGFR pathway andpancreatic cancers with activating aberrations of MAPK pathway includingK-Ras mutations.

The combination of the present disclosure may be useful in the treatmentof cancers that have activating mutations of PI3K. These include, butnot limited to, breast cancer, endometrium cancer, urinary track cancer,melanoma, colon cancer, stomach cancer, cervical cancer, prostate cancerand ovarian cancer.

Examples of cancers which may be treated with a compound of the presentdisclosure include but are not limited to, carcinoma, for example acarcinoma of the bladder, breast, colon (e.g. colorectal carcinomas suchas colon adenocarcinoma and colon adenoma), kidney, epidermis, liver,lung (e.g. adenocarcinoma, small cell lung cancer and non-small celllung carcinomas), oesophagus, gall bladder, ovary, pancreas (e.g.exocrine pancreatic carcinoma), stomach, cervix, thyroid, nose, head andneck, prostate, and skin (e.g. squamous cell carcinoma). Other examplesof cancers that may be treated with a compound of the present disclosureinclude hematopoietic tumours of lymphoid lineage (e.g. leukemia, acutelymphocytic leukemia, mantle cell lymphoma, chronic lymphocyticleukaemia, B-cell lymphoma(such as diffuse large B cell lymphoma),T-cell lymphoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin'slymphoma, hairy cell lymphoma, and Burkett's lymphoma; hematopoietictumours of myeloid lineage, for example acute and chronic myelogenousleukemias, myelodysplastic syndrome, and promyelocytic leukemia. Othercancers include thyroid follicular cancer; a tumour of mesenchymalorigin, for example fibrosarcoma or habdomyosarcoma; a tumour of thecentral or peripheral nervous system, for example astrocytoma,neuroblastoma, glioma or schwannoma; neuroendocrine cancer; melanoma;prostate cancer; ovarian cancer; rhabdoid cancer; seminoma;teratocarcinoma; osteosarcoma; xeroderma pigmentosum; retinoblastoma;keratoctanthoma; thyroid follicular cancer; and Kaposi's sarcoma.

One group of cancers includes human breast cancers (e.g. ER positivebreast cancer, Her2 positive breast cancer, PI3K mutated breast cancer,primary breast tumours, node-negative breast cancer, invasive ductadenocarcinomas of the breast, non-endometrioid breast cancers); andendometrial cancers. Another sub-set of cancers wherein compounds havingCDK4/6 and/or PI3K inhibitory activity may be of particular therapeuticbenefit comprises glioblastoma multiforme, T cell ALL, sarcomas,familial melanoma and melanoma.

The combination of the present disclosure could also be useful in thetreatment of viral infections, for example herpes virus, pox virus,Epstein-Barr virus, Sindbis virus, adenovirus, HIV, HPV, HCV and HCMV;prevention of AIDS development in HIV-infected individuals; chronicinflammatory diseases, for example systemic lupus erythematosus,autoimmune mediated glomerulonephritis, rheumatoid arthritis, psoriasis,inflammatory bowel disease, and autoimmune diabetes mellitus;cardiovascular diseases for example cardiac hypertrophy, restenosis,atherosclerosis; neurodegenerative disorders, for example Alzheimer'sdisease, AIDS-related dementia, Parkinson's disease, amyotropic lateralsclerosis, retinitis pigmentosa, spinal muscular atropy and cerebellardegeneration; glomerulonephritis; myelodysplastic syndromes, ischemicinjury associated myocardial infarctions, stroke and reperfusion injury,arrhythmia, atherosclerosis, toxin-induced or alcohol related liverdiseases, haematological diseases, for example, chronic anemia andaplastic anemia; degenerative diseases of the musculoskeletal system,for example, osteoporosis and arthritis, aspirin-senstiverhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases,ophthalmic diseases including age related macular degeneration, uveitis,and cancer pain.

The phrase “pharmaceutically acceptable” refers to molecular entitiesand compositions that are physiologically tolerable and do not typicallyproduce an allergic or similar untoward reaction, such as gastric upset,dizziness and the like, when administered to a human. Preferably, asused herein, the term “pharmaceutically acceptable” means approved by aregulatory agency of the Federal or a state government or listed in theU.S. Pharmacopeia or other generally recognized pharmacopeia for use inanimals, and more particularly in humans.

The term “carrier” refers to a diluent, adjuvant, excipient, or vehiclewith which the compound is administered. Such pharmaceutical carrierscan be sterile liquids, such as water and oils, including those ofpetroleum, animal, vegetable or synthetic origin, such as peanut oil,soybean oil, mineral oil, sesame oil and the like. Water or aqueoussolution saline solutions and aqueous dextrose and glycerol solutionsare preferably employed as carriers, particularly for injectablesolutions. Suitable pharmaceutical carriers are described in“Remington's Pharmaceutical Sciences” by E. W. Martin.

The phrase “therapeutically effective amount” is used herein to mean anamount sufficient to reduce by at least about 15 percent, preferably byat least 50 percent, more preferably by at least 90 percent, and mostpreferably prevent, a clinically significant deficit in the activity,function and response of the host. Alternatively, a therapeuticallyeffective amount is sufficient to cause an improvement in a clinicallysignificant condition/symptom in the host.

“Agent” refers to all materials that may be used to preparepharmaceutical and diagnostic compositions, or that may be compounds,nucleic acids, polypeptides, fragments, isoforms, variants, or othermaterials that may be used independently for such purposes, all inaccordance with the present disclosure.

The present disclosure includes all pharmaceutically acceptableisotopically-labeled compounds of the disclosure, i.e. compounds ofFormula (I), wherein one or more atoms are replaced by atoms having thesame atomic number, but an atomic mass or mass number different from theatomic mass or mass number usually found in nature.

Examples of isotopes suitable for inclusion in the compounds of thedisclosure comprises isotopes of hydrogen, such as ²H and ³H, carbon,such as ¹¹C, ¹³C and ¹⁴C, chlorine, such as ³⁶Cl, fluorine, such as ¹⁸F,iodine, such as ¹²³I and ¹²⁵I, nitrogen, such as ¹³N and ¹⁵N, oxygen,such as ¹⁵O, ¹⁷O and ¹⁸O, phosphorus, such as ³²P, and sulphur, such as³⁵S.

Certain isotopically-labelled compounds of Formula (I), for example,those incorporating a radioactive isotope, are useful in drug and/orsubstrate tissue distribution studies. The radioactive isotopes tritium,i.e. ³H, and carbon-14, i.e. ¹⁴C, are particularly useful for thispurpose in view of their ease of incorporation and ready means ofdetection.

Substitution with heavier isotopes such as deuterium, i.e. ²H, mayafford certain therapeutic advantages resulting from greater metabolicstability, for example, increased in vivo half-life or reduced dosagerequirements, and hence may be preferred in some circumstances.

Substitution with positron emitting isotopes, such as ¹¹C, ¹⁸F, ¹⁵O and¹³N, can be useful in Positron Emission Topography (PET) studies forexamining substrate receptor occupancy.

Isotopically-labeled compounds of Formula (I) can generally be preparedby conventional techniques known to those skilled in the art or byprocesses analogous to those described in the accompanying Examples andPreparations using an appropriate isotopically-labeled reagents in placeof the non-labeled reagent previously employed.

Compound A can be synthesized, for example, as described inWO2010/020675 or PCT/US2011/032062.

Compound B1 can be synthesized, for example, as described inWO2007/084786.

Compound B2 can be synthesized, for example, as described inWO2010/029082.

EXAMPLES Example 1

Potential synergistic interactions between Compound A and Compound B1 orB2 combinations were assessed relative to the Loewe additivity modelusing CHALICE software, via a synergy score calculated from thedifferences between the observed and Loewe model values across theresponse matrix. Briefly, 9 titrating concentration ranging from 20 μMdiluted serially three folds for Compound A and 10 μM diluted serially 3folds for Compound B1 or B2, including 0 μM, were used. In a 96 wellplate, the 9 concentration points for each agent were mixed in a matrixformat, generating 81 combinations. This plate was used to treatMDA-MB-453 cells, and the resulting inhibition values were used byCHALICE software to generate Inhibition and ADD Excess Inhibitionmatrices, as well as the isobolograms. A more detailed explanation ofthe technique and calculation can be found in Lehar et al. “Synergisticdrug combinations improve therapeutic selectivity”, Nat. Biotechnol.2009, July; 27(7), 659-666, which is hereby incorporated by reference.

As illustrated by FIG. 1, inhibition matrix shows the actual inhibitionobserved by the CTG assay at the respective concentrations of thecompounds. ADD Excess inhibition shows the excess inhibition observedover the inhibition predicted by the Loewe additivity model. In additionto the matrices, one can use isobolograms to observe synergy. Theinhibition level for each isobologram was chosen manually so as toobserve the best synergistic effects. Isobologram was generated withCompound A concentrations shown on the x-axis and Compound B1 or B2concentrations shown on the y-axis. A straight line connecting theCompound A and the Compound B1 or B2 concentrations which produce thechosen level of inhibition represented growth inhibitions that werestrictly additive for the combinations. Plots placed below the line ofadditivity (more growth inhibition) represented synergistic growthinhibitions, while plots above the line of additivity (less growthinhibition) represented antagonistic growth inhibitions.

Synergic interaction is observed for the combination of Compound A andCompound B1 or B2 in the MDA-MB-453 cells.

Example 2

Potential synergistic interactions between Compound A and Compound B1 orB2 combinations were assessed relative to the Loewe additivity modelusing CHALICE software, via a synergy score calculated from thedifferences between the observed and Loewe model values across theresponse matrix. Briefly, 9 titrating concentration ranging from 20 μMdiluted serially three folds for Compound A and 20 μM diluted serially 3folds for Compound B1 or B2, including 0 μM, were used. In a 96 wellplate, the 9 concentration points for each agent were mixed in a matrixformat, generating 81 combinations. This plate was used to treat breastcancer HCT-116 cells, and the resulting inhibition values were used byCHALICE software to generate Inhibition and ADD Excess Inhibitionmatrices, as well as the isobolograms. A more detailed explanation ofthe technique and calculation can be found in Lehar et al. “Synergisticdrug combinations improve therapeutic selectivity”, Nat. Biotechnol.2009, July; 27(7), 659-666, which is hereby incorporated by reference.

As illustrated by FIG. 2, inhibition matrix shows the actual inhibitionobserved by the CTG assay at the respective concentrations of thecompounds. ADD Excess inhibition shows the excess inhibition observedover the inhibition predicted by the Loewe additivity model. In additionto the matrices, one can use isobolograms to observe synergy. Theinhibition level for each isobologram was chosen manually so as toobserve the best synergistic effects. Isobologram was generated withCompound A concentrations shown on the x-axis and Compound B1 or B2concentrations shown on the y-axis. A straight line connecting theCompound A and the Compound B1 or B2 concentrations which produce thechosen level of inhibition represented growth inhibitions that werestrictly additive for the combinations. Plots placed below the line ofadditivity (more growth inhibition) represented synergistic growthinhibitions, while plots above the line of additivity (less growthinhibition) represented antagonistic growth inhibitions.

Synergic interaction is observed for the combination of Compound A andCompound B1 or B2 in the HCT-116 cells.

Example 3

Potential synergistic interactions between Compound A and Compound B1 orB2 combinations were assessed relative to the Loewe additivity modelusing CHALICE software, via a synergy score calculated from thedifferences between the observed and Loewe model values across theresponse matrix. Briefly, 9 titrating concentration ranging from 20 μMdiluted serially three folds for Compound A and 20 μM diluted serially 3folds for Compound B1 or B2, including 0 μM, were used. In a 96 wellplate, the 9 concentration points for each agent were mixed in a matrixformat, generating 81 combinations. This plate was used to treat ERpositive breast cancer MCF-7 cells, and the resulting inhibition valueswere used by CHALICE software to generate Inhibition and ADD ExcessInhibition matrices, as well as the isobolograms. A more detailedexplanation of the technique and calculation can be found in Lehar etal. “Synergistic drug combinations improve therapeutic selectivity”,Nat. Biotechnol. 2009, July; 27(7), 659-666, which is herebyincorporated by reference.

As illustrated by FIG. 3, inhibition matrix shows the actual inhibitionobserved by the BrdU assay at the respective concentrations of thecompounds. ADD Excess inhibition shows the excess inhibition observedover the inhibition predicted by the Loewe additivity model. In additionto the matrices, one can use isobolograms to observe synergy. Theinhibition level for each isobologram was chosen manually so as toobserve the best synergistic effects. Isobologram was generated withCompound A concentrations shown on the x-axis and Compound B1 or B2concentrations shown on the y-axis. A straight line connecting theCompound A and the Compound B1 or B2 concentrations which produce thechosen level of inhibition represented growth inhibitions that werestrictly additive for the combinations. Plots placed below the line ofadditivity (more growth inhibition) represented synergistic growthinhibitions, while plots above the line of additivity (less growthinhibition) represented antagonistic growth inhibitions.

Synergic interaction is observed for the combination of Compound A andCompound B1 or B2 in the MCF-7 cells.

Example 4

Potential synergistic interactions between Compound A and Compound B2combinations were assessed relative to the Loewe additivity model usingCHALICE software, via a synergy score calculated from the differencesbetween the observed and Loewe model values across the response matrix.Briefly, 9 titrating concentration ranging from 20 μM diluted seriallythree folds for Compound A and 20 μM diluted serially 3 folds forCompound B2, including 0 μM, were used. In a 96 well plate, the 9concentration points for each agent were mixed in a matrix format,generating 81 combinations. This plate was used to treat ER positivebreast cancer T47-D cells, and the resulting inhibition values were usedby CHALICE software to generate Inhibition and ADD Excess Inhibitionmatrices, as well as the isobolograms. A more detailed explanation ofthe technique and calculation can be found in Lehar et al. “Synergisticdrug combinations improve therapeutic selectivity”, Nat. Biotechnol.2009, July; 27(7), 659-666, which is hereby incorporated by reference.

As illustrated by FIG. 4, inhibition matrix shows the actual inhibitionobserved by the BrdU assay at the respective concentrations of thecompounds. ADD Excess inhibition shows the excess inhibition observedover the inhibition predicted by the Loewe additivity model. In additionto the matrices, one can use isobolograms to observe synergy. Theinhibition level for each isobologram was chosen manually so as toobserve the best synergistic effects. Isobologram was generated withCompound A concentrations shown on the x-axis and Compound B2concentrations shown on the y-axis. A straight line connecting theCompound A and the Compound B2 concentrations which produce the chosenlevel of inhibition represented growth inhibitions that were strictlyadditive for the combinations. Plots placed below the line of additivity(more growth inhibition) represented synergistic growth inhibitions,while plots above the line of additivity (less growth inhibition)represented antagonistic growth inhibitions.

Synergic interaction is observed for the combination of Compound A andCompound B2 in the T47-D cells.

1. A combination comprising a first agent that is a cyclin dependentkinase 4 or cyclin dependent kinase 6 (CDK4/6) inhibitor and a secondagent that is a PI3Kinase inhibitor.
 2. The combination of claim 1wherein the first agent is Compound A described by Formula A:

or a pharmaceutically acceptable salt thereof.
 3. The combination ofclaim 1, wherein the second agent is Compound B1 described by FormulaB1:

or a pharmaceutical acceptable salt thereof.
 4. The combination of claim1, wherein the second agent is Compound B2 described by Formula B2;

or a pharmaceutical acceptable salt thereof.
 5. The use of thecombination according to claim 1 for the manufacture of a medicament,wherein the medicament is for treating cancer.
 6. The use of claim 5,wherein the cancer is a solid tumor cancer.
 7. The use of claim 6,wherein the cancer Is pancreatic cancer, breast cancer, mantle celllymphoma, lung cancer, melanoma, colon cancer, esophageal cancer,endometrial cancer, head and neck cancer, sarcomas, multiple myeloma,leukemia, urinary track cancer, renal cell carcinoma, gastric cancer,glioblastoma, hepatocellular carcinoma, gastric cancer, cervical cancer,neuroblastoma, neuroendocrine cancer, rhabdoid cancer, prostate canceror ovarian cancer.
 8. The use of claim 7, wherein the cancer ispancreatic cancer, breast cancer, or mantle ceil lymphoma.
 9. The use ofclaim 8, wherein the cancer is a lymphoma.
 10. The use of claim 8,wherein the cancer is breast cancer.
 11. The use of claim 10, whereinthe breast cancer is ER positive breast cancer.
 12. The use of ciaim 10,wherein the breast cancer is Her2 positive breast cancer.
 13. The use ofclaim 10, wherein the breast cancer is PI3K mutated breast cancer.